Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus

Table 1 Development of adenocarcinoma

Ref.	Number of patients	Incidence of adenocarcinoma (n/yr follow-up)	Annual incidence of adenocarcinoma (95%CI)1	Number of cancers expected to develop (95%CI)	Individual’s lifetime risk of adenocarcinoma (95%CI)
Desai et al[5]	11434	186/58547	0.32% (0.27-0.37)	557 (479-643)	0.071 (0.061-0.082)
Yousef et al[6]	11279	209/47496	0.44% (0.38-0.50)	771 (670-883)	0.098 (0.085-0.112)
Sikkema et al[7]	14109	344/61804	0.56% (0.50-0.62)	975 (874-1084)	0.124 (0.111-0.138)
Thomas et al[8]	9469	186/36635	0.51% (0.44-0.59)	890 (766-1027)	0.113 (0.097-0.130)
Gatenby et al[3]	807	23/3912	0.59% (0.38-0.87)	1030 (653-1546)	0.131 (0.083-0.196)

¹95%CI evaluated using an exact poisson distribution.

Table 2 Development of high-grade dysplasia and adenocarcinoma

Ref.	Number of patients	Incidence of high-grade dysplasia or adenocarcinoma (n/yr follow-up)	Annual incidence of high-grade dysplasia or adenocarcinoma (95%CI)1	Number of cases expected to develop high-grade dysplasia or adenocarcinoma (95%CI)	Individual’s lifetime risk of developing high-grade dysplasia or adenocarcinoma (95%CI)
Yousef et al[6] 2008	4491	178/22609	0.79% (0.67-0.91)	1379 (1184-1598)	0.175 (0.150-0.203)
Sikkema et al[7] 2010	4528	194/22559	0.86% (0.74-0.99)	1506 (1302-1734)	0.191 (0.165-0.220)
Thomas et al[8] 2007			0.9%	1577	0.200
Gatenby et al[3] 2008	806	39/3908	1.0% (0.71-1.4)	1748 (1243-2390)	0.222 (0.158-0.303)

¹95%CI evaluated using an exact poisson distribution.